# Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

> **NCT06690047** · PHASE4 · COMPLETED · sponsor: **Bernstein Clinical Research Center** · enrollment: 5 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **BIOLOGICAL:** Ruconest

## Key facts

- **NCT ID:** NCT06690047
- **Lead sponsor:** Bernstein Clinical Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-14
- **Primary completion:** 2022-04-28
- **Final completion:** 2022-04-28
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06690047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06690047, "Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06690047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*